CASI Pharmaceuticals, Inc (DE)
CASIDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000895051
CASI Pharmaceuticals, Inc (DE) was delisted in 2023; its insiders filed their last Form 4 on Sep 9, 2022; 23 institutions reported holding it in 13F filings for Q4 2022, worth $3.31M in total; no superinvestor held it.
Q3 2022 vs. Q2 2022
How the institutions holding CASI Pharmaceuticals, Inc (DE) changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 24 | 24 | 0 |
| Shares | 2.19M | 1.99M | −200.1K (−9.1%) |
| Value | $6.26M | $5.17M | −$1.09M (−17.4%) |
New holders (6)
Institutions that held CASI Pharmaceuticals, Inc (DE) at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 33,637 | $87.0K | 0.00% |
| Prudential Financial Inc | 11,000 | $29.0K | 0.00% |
| Renaissance Technologies LLC | 10,400 | $27.0K | 0.00% |
| UBS Group AG | 3,089 | $8.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 134 | $348 | 0.00% |
| IFP Advisors, Inc | 9 | – | – |
Sold out (6)
Institutions that held CASI Pharmaceuticals, Inc (DE) at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Ikarian Capital, LLC | 132,014 | $378.0K |
| Bailard, Inc. | 31,530 | $90.0K |
| RBF Capital, LLC | 15,936 | $46.0K |
| Boothbay Fund Management, LLC | 11,686 | $33.0K |
| Credit Suisse AG | 2,797 | $8.00K |
| Captrust Financial Advisors | 150 | $0 |